Verapamil synergistically enhances cytotoxicity of bortezomib in mantle cell lymphoma via induction of reactive oxygen species production.
作者信息
Chen Zheng, Romaguera Jorge, Wang Michael, Fayad Luis, Kwak Larry W, McCarty Nami
出版信息
Br J Haematol. 2012 Oct;159(2):243-6. doi: 10.1111/bjh.12003. Epub 2012 Aug 24.
Abstract
摘要
相似文献
1
Verapamil synergistically enhances cytotoxicity of bortezomib in mantle cell lymphoma via induction of reactive oxygen species production.维拉帕米通过诱导活性氧生成，协同增强硼替佐米对套细胞淋巴瘤的细胞毒性。
Br J Haematol. 2012 Oct;159(2):243-6. doi: 10.1111/bjh.12003. Epub 2012 Aug 24.
2
The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib.布鲁顿酪氨酸激酶（BTK）抑制剂 PCI-32765 与蛋白酶体抑制剂协同作用，增加对硼替佐米敏感或耐药的弥漫性大 B 细胞淋巴瘤（DLBCL）和套细胞淋巴瘤（MCL）细胞的活性。
Br J Haematol. 2013 Apr;161(1):43-56. doi: 10.1111/bjh.12206. Epub 2013 Jan 30.
3
The HB22.7 Anti-CD22 monoclonal antibody enhances bortezomib-mediated lymphomacidal activity in a sequence dependent manner.HB22.7 抗 CD22 单克隆抗体以序列依赖性方式增强硼替佐米介导的淋巴瘤杀伤活性。
J Hematol Oncol. 2011 Dec 1;4:49. doi: 10.1186/1756-8722-4-49.
4
The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status.蛋白酶体抑制剂硼替佐米通过产生活性氧和激活Noxa诱导套细胞淋巴瘤细胞凋亡，且不依赖于p53状态。
Blood. 2006 Jan 1;107(1):257-64. doi: 10.1182/blood-2005-05-2091. Epub 2005 Sep 15.
5
The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak.BH3模拟物GX15-070通过增强Noxa介导的Bak激活，与硼替佐米协同作用于套细胞淋巴瘤。
Blood. 2007 May 15;109(10):4441-9. doi: 10.1182/blood-2006-07-034173. Epub 2007 Jan 16.
6
PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells.PCI-24781通过核因子κB机制诱导胱天蛋白酶和活性氧依赖性凋亡，并且在淋巴瘤细胞中与硼替佐米具有协同作用。
Clin Cancer Res. 2009 May 15;15(10):3354-65. doi: 10.1158/1078-0432.CCR-08-2365. Epub 2009 May 5.
7
Nuclear translocation of B-cell-specific transcription factor, BACH2, modulates ROS mediated cytotoxic responses in mantle cell lymphoma.B 细胞特异性转录因子 BACH2 的核转位调节套细胞淋巴瘤中 ROS 介导的细胞毒性反应。
PLoS One. 2013 Aug 2;8(8):e69126. doi: 10.1371/journal.pone.0069126. Print 2013.
8
Degrasyn potentiates the antitumor effects of bortezomib in mantle cell lymphoma cells in vitro and in vivo: therapeutic implications.地瑞那新增强硼替佐米在体外和体内套细胞淋巴瘤细胞中的抗肿瘤作用：治疗意义。
Mol Cancer Ther. 2010 Jul;9(7):2026-36. doi: 10.1158/1535-7163.MCT-10-0238. Epub 2010 Jul 6.
9
Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.组蛋白去乙酰化酶抑制剂SAHA与蛋白酶体抑制剂硼替佐米在套细胞淋巴瘤中的协同相互作用
Eur J Haematol. 2008 Feb;80(2):133-42. doi: 10.1111/j.1600-0609.2007.00995.x. Epub 2007 Dec 20.
10
Bortezomib and fenretinide induce synergistic cytotoxicity in mantle cell lymphoma through apoptosis, cell-cycle dysregulation, and IκBα kinase downregulation.硼替佐米和维甲酸通过诱导凋亡、细胞周期失调以及IκBα激酶下调，从而在套细胞淋巴瘤中产生协同细胞毒性作用。
Anticancer Drugs. 2015 Oct;26(9):974-83. doi: 10.1097/CAD.0000000000000274.
引用本文的文献
1
Targeting HSP47 and HSP70: promising therapeutic approaches in liver fibrosis management.靶向 HSP47 和 HSP70：肝纤维化治疗中有前途的治疗方法。
J Transl Med. 2022 Nov 26;20(1):544. doi: 10.1186/s12967-022-03759-z.
2
P-Glycoprotein Inhibition Sensitizes Human Breast Cancer Cells to Proteasome Inhibitors.P-糖蛋白抑制使人类乳腺癌细胞对蛋白酶体抑制剂敏感。
J Cell Biochem. 2017 May;118(5):1239-1248. doi: 10.1002/jcb.25783. Epub 2017 Jan 10.
3
ROS-Induced CXCR4 Signaling Regulates Mantle Cell Lymphoma (MCL) Cell Survival and Drug Resistance in the Bone Marrow Microenvironment via Autophagy.活性氧诱导的CXCR4信号通过自噬调节骨髓微环境中的套细胞淋巴瘤（MCL）细胞存活和耐药性。
Clin Cancer Res. 2016 Jan 1;22(1):187-99. doi: 10.1158/1078-0432.CCR-15-0987. Epub 2015 Sep 8.
4
Nuclear translocation of B-cell-specific transcription factor, BACH2, modulates ROS mediated cytotoxic responses in mantle cell lymphoma.B 细胞特异性转录因子 BACH2 的核转位调节套细胞淋巴瘤中 ROS 介导的细胞毒性反应。
PLoS One. 2013 Aug 2;8(8):e69126. doi: 10.1371/journal.pone.0069126. Print 2013.
本文引用的文献
1
Stem-like tumor cells confer drug resistant properties to mantle cell lymphoma.类干细胞肿瘤细胞赋予套细胞淋巴瘤耐药特性。
Leuk Lymphoma. 2011 Jun;52(6):1066-79. doi: 10.3109/10428194.2011.562570.
2
Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma.硼替佐米耐药性组成型核因子κB活性在套细胞淋巴瘤中的患病率
Mol Cancer. 2008 May 19;7:40. doi: 10.1186/1476-4598-7-40.
3
Advances in the understanding of mantle cell lymphoma.套细胞淋巴瘤研究进展。
Br J Haematol. 2008 Jun;142(2):149-65. doi: 10.1111/j.1365-2141.2008.07124.x. Epub 2008 Apr 10.
4
Endoplasmic reticulum stress and oxidative stress: a vicious cycle or a double-edged sword?内质网应激与氧化应激：恶性循环还是双刃剑？
Antioxid Redox Signal. 2007 Dec;9(12):2277-93. doi: 10.1089/ars.2007.1782.
5
Bortezomib for the treatment of mantle cell lymphoma.硼替佐米用于治疗套细胞淋巴瘤。
Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5291-4. doi: 10.1158/1078-0432.CCR-07-0871.
6
Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells.蛋白酶体抑制剂在多发性骨髓瘤细胞中诱导终末未折叠蛋白反应。
Blood. 2006 Jun 15;107(12):4907-16. doi: 10.1182/blood-2005-08-3531. Epub 2006 Feb 28.
7
NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation.核因子-κB抗凋亡作用：诱导肿瘤坏死因子受体相关因子1和2以及细胞凋亡抑制蛋白1和2以抑制半胱天冬酶-8激活。
Science. 1998 Sep 11;281(5383):1680-3. doi: 10.1126/science.281.5383.1680.
8
Activation of interleukin-6 gene expression through the NF-kappa B transcription factor.通过核因子-κB转录因子激活白细胞介素-6基因表达。
Mol Cell Biol. 1990 May;10(5):2327-34. doi: 10.1128/mcb.10.5.2327-2334.1990.
Zotero 插件